Study of effects of vitamin D on some genes expression in multiple sclerosis patients

Study of effects of vitamin D on IL2,IL4, IL-6 ,IL-17A,CYP27A1 and CYP27B1 genes expression in multiple sclerosis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014081818840N1

Enrollment

Registered

2014-09-28

Start date

2012-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

vitamin D, 50000 IU /a week , 8 weeks.

Treatment - Drugs

vitamin D, 50000 IU /a week , 8 weeks

Eligibility

Sex/Gender

All

Age

22 Years to 52 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: relapsing-remitting multiple sclerosis patients; MS patients with vitamin D deficiency (<80ng/ml). Exclusion criteria: patients treated with vitamin D supplements; progressive MS; relapsed patients, psychiatric patients and the patients who are taken steroid drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Expression of IL2 gene. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: taking of blood from patients and measurment of mRNA level.	—

Secondary

Measure	Time frame
Expression of IL4 ,IL6,IL17A,CYP27A1 and CYP27B1. Timepoint: before vitamin D treatment and two month after treatment. Method of measurement: taking of blood from patients and measurement of mRNA level.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahar Naghavi Gargari

Tarbiat Modares University

bahar.naghavigargari@modares.ac.ir+98 21 8288 4477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026